| Previous Section | Index | Home Page |
14 May 2007 : Column 592W—continued
In Vitro Fertilisation
Jim Dobbin: To ask the Secretary of State for Health how many human embryos were created in each year since the passage of the Human Fertilisation and Embryology Act 1990; and how many of these embryos have been brought to birth. [136746]
Caroline Flint: Information on the number of embryos that developed to a live birth is not held centrally nor by the Human Fertilisation and Embryology Authority (HFEA). Data on the total number of treatment cycles, the number resulting in a live birth and the number of embryos created are shown in the following table.
| Total number of in vitro fertilisation (IVF) treatment cycles, embryos created and treatments resulting in live births 1991 to 2004( 1) | |||||||
| Treatments involving fresh (non- frozen) embryos | Treatments involving frozen embryos( 2) | Non-treatment( 3) | |||||
| Year (calendar) | Treatment cycles | Embryos created | Treatment cycles with live birth outcome | Treatment cycles | Treatment cycles with live birth outcome | Non- treatment cycles | Embryos created |
| (1 )2004 is the most recent year for which information is available. (2 )Embryos used in these cycles may have been created in previous years as part of fresh treatment cycles. (3 )These are IVF cycles that, although started, did not progress to embryo transfer. These embryos may have been used in a patient’s later frozen treatment cycles or for embryo donation. No data is held for years 1991-1998. Source: HFEA | |||||||
Incontinence: Medical Equipment
Annette Brooke: To ask the Secretary of State for Health whether her Department has made an assessment of the effects on children aged between five and 16 years of age and their families of the changes to the current provision of continence appliances and products proposed in the consultation on arrangements for the reimbursement pricing of stoma and incontinence appliances under Part IX of the drug tariff. [130365]
Caroline Flint: In reviewing the arrangements under Part IX of the Drug Tariff for the provision of stoma and incontinence appliances, and related services, the Department has always made it clear that a key objective has been to maintain and, where appropriate, to improve patient care. This objective embraces all patient groups, including young people.
Influenza: Vaccination
Mr. Lansley: To ask the Secretary of State for Health pursuant to the answer of 22 November 2006, Official Report, column 139W, on influenza, what steps she is taking to meet the World Health Organisation’s target of vaccinating 75 per cent. of high risk groups against seasonal influenza, in addition to the elderly. [131899]
Caroline Flint: In 2003, the World Health Assembly urged member states with influenza vaccination policies to increase vaccination coverage of all people in high risk groups. The 75 per cent. uptake target set by the World Health Organisation (WHO) was for the elderly to be reached by 2010. This target was achieved in 2005-06, when uptake in those aged 65 and over reached 75.3 per cent.
WHO did not set a target for those less than 65 years with risk factors.
Mr. Lansley: To ask the Secretary of State for Health what proportion of (a) those aged 65 and over and (b) those aged under 65 and judged to be clinically at risk were immunised against seasonal influenza in each year since 2000-01. [135875]
Caroline Flint: The proportion of influenza vaccine uptake in those aged 65 and over and those aged under 65 and judged to be clinically at risk since 2000-01 is shown as follows.
| Uptake in those aged 65 years and over | |
| Percentage | |
| Uptake in clinical risk groups aged under 65 years | |
| Percentage | |
| (1) Data not collected. Note: These data are collected by the Health Protection Agency. | |
Insulin
Mr. Hollobone: To ask the Secretary of State for Health pursuant to the Answer of 17 April 2007, Official Report, column 585W, on insulin, what the last five dates were on which her Department’s officials discussed with the National Institute for Health and Clinical Excellence its future programme on insulin treatments. [136869]
Caroline Flint: Dr. Sue Roberts the National Clinical Director for Diabetes and Dr. Nick Summerton, Consultant Clinical and Public Health Advisor (Topic Selection) at the National Institute for Health and Clinical Excellence have met on the following occasions, where a range of issues were discussed:
16 November 2006;
17 November 2006;
9 January 2007;
1 February 2007; and
7 March 2007.
Life Expectancy
David Simpson: To ask the Secretary of State for Health what research her Department undertook to investigate differences in life expectancy in different parts of the UK in each of the last five years. [132252]
Caroline Flint: The Department has not over the last five years commissioned generic research of the sort to which the hon. Gentleman refers.
Lung Cancer: NICE
Mr. Leech: To ask the Secretary of State for Health what estimate she has made of the financial impact on the NHS of positive National Institute for Health and Clinical Excellence appraisals for medicines for lung cancer. [129814]
Caroline Flint: There is currently no extant completed technology appraisal from the National Institute for Health and Clinical Excellence (NICE) of medicines for lung cancer. However, NICE published an appraisal of docetaxel, paclitaxel, gemcitabine, and vinorelbine for non small-cell lung cancer in June 2001. This appraisal was updated by and incorporated into the clinical guideline on lung cancer published in February 2005. NICE’s estimate of full-year costs in England and Wales was £9.55 million.
NICE is currently undertaking two Single Technology Appraisals (STAs) on Tarceva and Alimta for non small-cell lung cancer.
Maternity Services
Mr. Lansley: To ask the Secretary of State for Health what discussions (a) Ministers and (b) officials held with the National Institute for Health and Clinical Excellence on the decision by the Institute to reopen its consultation on chapter three of its draft clinical guidance on intrapartum care. [131957]
Caroline Flint: Departmental officials were made aware of the National Institute for Health and Clinical Excellence’s (NICE) decision to issue a further consultation document on chapter three of its draft clinical guidance on intrapartum care shortly before that document was published. Ministers have held no discussions with NICE on this issue.
Mr. Stewart Jackson: To ask the Secretary of State for Health if she will assess the adequacy of the policy of not centrally collecting and collating data on the transportation of premature babies under NHS care between health trusts; and if she will make a statement. [135456]
Mr. Ivan Lewis: Although we do not collect data centrally on the transportation of premature babies, that is not to say that we do not consider that this is an important issue. Safety has always been a Government priority. “Maternity Matters: Choice, access and continuity of care in a safe service”, published on 3 April, ensures that there will be more flexible and accessible maternity services, which will better meet the needs of local families and improve their experience of care, driving up the quality and efficiency of services. Through “Safety first: a report for patients, clinicians and healthcare managers” specialist support is provided at local national health service organisation levels in identifying patient safety risks, implementing solutions and sharing the learning. In addition, the National Audit Office (NAO) is undertaking a value for money study into neonatal services in England. The NAO will consider transport issues as part of their deliberations.
| Next Section | Index | Home Page |